Create a free research account to view current pricing and place an order.
How does Tirzepatide work in research models?
Tirzepatide is a dual GIP and GLP receptor agonist. Combined incretin signaling affects pancreatic insulin secretion, glucagon dynamics, gastric-emptying tone, hypothalamic satiety signaling, and adipocyte nutrient-partitioning pathways.
What is the half-life of Tirzepatide?
Half-life: Approx. 5-6 days.
Approximate half-life is 5-6 days. Median time to maximum concentration is about 24 hours with a reported range of roughly 8-72 hours; steady state is typically achieved after about 4 weeks of once-weekly administration.
Research dosing reference
2.5-15 mg once weekly; escalate gradually based on tolerance.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 2.5 mg | 50 units |
| 5 mg | 100 units |
| 10 mg | 200 units |
| 15 mg | 300 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
How is Tirzepatide reconstituted?
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
| 20 mg | 2 mL BAC Water | 0.100 mg/unit |
| 30 mg | 3 mL BAC Water preferred for cleaner concentration interpretation | 0.100 mg/unit |
| 60 mg | 3 mL BAC Water preferred for cleaner concentration interpretation | 0.200 mg/unit |
Injection timing
Once weekly on a consistent day. Time of day is less important than consistency; choose timing that minimizes nausea disruption.
Beginner escalation
Start at the lowest practical exposure and hold each step long enough to evaluate GI tolerance before increasing.
Side-effect mitigation
Monitor nausea, reflux, constipation, reduced appetite, hydration status, fatigue, and delayed gastric emptying. Slow escalation and hydration/electrolytes are primary mitigation tools.
Stack compatibility
Avoid stacking overlapping incretin agonists unless intentionally structured and clinician supervised. Pathway contrast with GH-axis, mitochondrial, or lipolysis adjuncts is generally cleaner than incretin overlap.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Long-term metabolic protocols should include reassessment every 8-12 weeks: GI tolerance, hydration, appetite adaptation, body-composition response, metabolic markers, and whether escalation is still needed. Avoid continuous escalation without objective review.
Frequently asked questions
What is Tirzepatide and how is it studied?
Tirzepatide is a dual GIP and GLP receptor agonist. Combined incretin signaling affects pancreatic insulin secretion, glucagon dynamics, gastric-emptying tone, hypothalamic satiety signaling, and adipocyte nutrient-partitioning pathways. Tirzepatide is catalogued in the GLP / Metabolic group of this reference and is studied in laboratory and in-vitro models only.
What is known about the half-life of Tirzepatide?
Reference half-life for Tirzepatide: approx. 5-6 days. Approximate half-life is 5-6 days. Published pharmacokinetic figures come from research and clinical-literature contexts and are listed here as reference values for laboratory work only, not as guidance for any person or animal.
How is Tirzepatide stored?
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically. Lyophilized research peptides are generally kept cold, dry, and away from light, and reconstituted solutions are labeled with concentration and date. Follow the storage conditions documented for the specific lot you receive.
How is Tirzepatide reconstituted for laboratory work?
The reference reconstitution for the 10 mg vial is 2 mL BAC Water, which gives a concentration of about 5 mg/mL. Concentration equals peptide mass divided by diluent volume, so adding more liquid lowers the concentration. Add diluent slowly down the vial wall, swirl rather than shake, and confirm the arithmetic before preparing any research solution.
Is Tirzepatide FDA approved?
No. The research-grade Tirzepatide described here is an investigational, research-use-only material and is not an FDA-approved drug product. Where an approved pharmaceutical form of a compound exists, it is a separate prescription product. This reference is not medical advice, and the material is not for human or animal consumption.
Tirzepatide product overview · Tirzepatide cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration